Oracle Investment Management
Latest statistics and disclosures from Oracle Investment Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are WGS, BHVN, Biohaven, PHAT, Spdr S&p Oil & Gas Exp & Pr call, and represent 70.82% of Oracle Investment Management's stock portfolio.
- Added to shares of these 10 stocks: Spdr S&p Oil & Gas Exp & Pr call (+$9.9M), PHAT (+$9.5M), Biohaven (+$9.4M), Novavax Inc call (+$6.8M), Phathom Pharmaceuticals Inc call, MYGN, Ardelyx Inc call, PLTR, PACB, BHVN.
- Started 4 new stock positions in Phathom Pharmaceuticals Inc call, PLTR, Spdr S&p Oil & Gas Exp & Pr call, Novavax Inc call.
- Reduced shares in these 10 stocks: SWTX (-$6.4M), WGS, PLTR, , EYPT, ARDX, Eyepoint Pharmaceuticals, Springworks Therapeutics, WBA, AGEN.
- Sold out of its positions in AGEN, Myriad Genetics Inc option, Springworks Therapeutics, WBA.
- Oracle Investment Management was a net buyer of stock by $27M.
- Oracle Investment Management has $167M in assets under management (AUM), dropping by 55.68%.
- Central Index Key (CIK): 0001012622
Tip: Access up to 7 years of quarterly data
Positions held by Oracle Investment Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Oracle Investment Management
Oracle Investment Management holds 22 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Genedx Holdings Corp Com Cl A (WGS) | 26.6 | $44M | -5% | 1.0M | 42.44 |
|
| Biohaven (BHVN) | 21.1 | $35M | 705k | 49.97 |
|
|
| Biohaven Call Call Option | 9.1 | $15M | +163% | 303k | 49.97 |
|
| Phathom Pharmaceuticals (PHAT) | 8.1 | $14M | +233% | 750k | 18.08 |
|
| Spdr Ser Tr Call Call Option | 5.9 | $9.9M | NEW | 100k | 98.80 |
|
| Ardelyx (ARDX) | 5.7 | $9.4M | -7% | 1.4M | 6.89 |
|
| Novavax Call Call Option | 4.0 | $6.8M | NEW | 535k | 12.63 |
|
| Quidel Corp (QDEL) | 3.2 | $5.4M | 118k | 45.60 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 2.4 | $4.1M | 536k | 7.60 |
|
|
| Myriad Genetics (MYGN) | 2.2 | $3.7M | +124% | 135k | 27.39 |
|
| Phathom Pharmaceuticals Call Call Option | 2.1 | $3.5M | NEW | 193k | 18.08 |
|
| Ardelyx Call Call Option | 1.8 | $3.0M | +65% | 430k | 6.89 |
|
| Forian Ord (FORA) | 1.8 | $2.9M | 1.4M | 2.16 |
|
|
| Eyepoint Pharmaceuticals Call Call Option | 1.7 | $2.8M | -20% | 350k | 7.99 |
|
| Cava Group Ord (CAVA) | 1.4 | $2.3M | 19k | 123.85 |
|
|
| Pacific Biosciences of California (PACB) | 0.7 | $1.2M | +72% | 728k | 1.70 |
|
| Springworks Therapeutics (SWTX) | 0.7 | $1.1M | -85% | 34k | 32.04 |
|
| Palantir Technologies Cl A (PLTR) | 0.6 | $1.0M | NEW | 28k | 37.20 |
|
| Palantir Technologies Call Call Option | 0.4 | $744k | -71% | 20k | 37.20 |
|
| Biogen Idec (BIIB) | 0.3 | $468k | 2.4k | 193.84 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $260k | -85% | 33k | 7.99 |
|
| Biodesix (BDSX) | 0.0 | $52k | 29k | 1.78 |
|
Past Filings by Oracle Investment Management
SEC 13F filings are viewable for Oracle Investment Management going back to 2010
- Oracle Investment Management 2024 Q3 filed Nov. 14, 2024
- Oracle Investment Management 2024 Q2 filed Aug. 14, 2024
- Oracle Investment Management 2024 Q1 filed May 15, 2024
- Oracle Investment Management 2023 Q4 filed Feb. 14, 2024
- Oracle Investment Management 2023 Q3 filed Nov. 14, 2023
- Oracle Investment Management 2023 Q2 filed Aug. 14, 2023
- Oracle Investment Management 2023 Q1 filed May 15, 2023
- Oracle Investment Management 2022 Q4 filed Feb. 14, 2023
- Oracle Investment Management 2022 Q3 filed Nov. 14, 2022
- Oracle Investment Management 2022 Q2 filed Aug. 15, 2022
- Oracle Investment Management 2022 Q1 filed May 16, 2022
- Oracle Investment Management 2021 Q4 filed Feb. 14, 2022
- Oracle Investment Management 2021 Q3 filed Nov. 15, 2021
- Oracle Investment Management 2021 Q2 filed Aug. 16, 2021
- Oracle Investment Management 2021 Q1 filed May 17, 2021
- Oracle Investment Management 2020 Q4 filed Feb. 16, 2021